Descrizione del progetto
Standardizzazione di saggi basati su organoidi per la diagnosi clinica
Gli organoidi sono mimetici miniaturizzati in vitro di organi derivati da cellule staminali corrispondenti. Sono stati utilizzati per studiare la fisiologia degli organi e la biologia delle malattie, nonché per la scoperta di farmaci. L’obiettivo del progetto Gri3D, finanziato dall’UE, è rendere questa tecnologia facile da utilizzare per poi trasferirla nel settore sanitario. Il gruppo responsabile del progetto ha generato una piattaforma di idrogel biocompatibile per la coltivazione di organoidi in modo standardizzato, adatta per la diagnostica clinica e lo screening di farmaci. La produzione sarà portata a un livello industriale e, dopo una valutazione tecnica ed economica, i saggi basati su organoidi saranno pronti per la commercializzazione.
Obiettivo
The ability to generate miniature organ models in a dish, termed organoids, from patient stem cells has opened endless possibilities for applications in precision medicine. SUN bioscience SA, a spin-off company of EPFL in Switzerland, was founded in 2016 with the ambition to move these organoid cultures from basic research to the Health Care industry.
To reach this goal, SUN bioscience has developed Gri3D, a microstructured biocompatible hydrogel platform, and aims to establish this technology as a new standard for growing organoids at industrial scale and precision. Gri3D prototypes have been field tested with over 30 European academic and pharmaceutical R&D groups. In addition, SUN bioscience has developed an industrial automated manufacturing mechanism for Gri3D that is now being translated into the world-wide first machine, Hydra I, that auomates liquid handling with hydrogel microembossing.
The objective of this feasibility study is to verify the technical, economical and practical viability of Gri3D and to ensure its successful market entry in Europe. Specifically, the first step is to validate the production capacity of Hydra I by producing 1’000 Gri3D units, which corresponds to one tenth of the total annual target production volume.
In a second step, SUN bioscience aims to validate the market by commercializing these 1’000 Gri3D units to existing customers and to expand its customer base to a total of 20-40 recurrent clients.
According to our current strategy, SUN bioscience will run at maximum single line production capacity with cumulative revenues of >€2M within 3 years after market introduction of Gri3D. The 3D technologies market is expected to reach €600M by 2021. The long-term business objective is to implement organoid assays on Gri3D and to establish SUN bioscience as a leader in clinical diagnostics with the intention to initiate a phase 2 SME instrument project along this path.
Campo scientifico
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health scienceshealth sciencespersonalized medicine
- social scienceseconomics and businesseconomicssustainable economy
Programma(i)
- H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme
- H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing
- H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
- H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEINST-1-2016-2017
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
1015 LAUSANNE
Svizzera
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.